arrow
F

Felix Dietlein

Harvard Medical School
H指数:26
被引数:4,033

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Auger-Emitting Radionuclides in Radiopharmaceutical Research: Decay-Associated Processes, Vector-Dependent Localization, and Translational Perspectives

俄歇发射放射性核素在放射性药物研究中的应用:衰变相关过程、载体依赖性定位及转化研究视角

2026-08-120
OAAI
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer

单细胞转录组学揭示FXR1可作为卵巢癌中siRNA疗法的可操作靶点

2026-04-030
OAAI
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy

你知道你的psma-tracer吗?不同PSMA配体的生物分布的变异性及其对PSMA靶向治疗前定义PSMA阳性的潜在影响

2025-01-100
OAAI
Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis
2024-05-221
OAAI
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology

通过分子肿瘤学年鉴将分子概况整合到临床框架中,以前瞻性地指导精确肿瘤学

2021-09-3019
OA
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival
2021-06-0714
OAAI
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019)
2020-06-196
OAAI
Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC
2020-04-0122
OA
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

转移性黑色素瘤患者PD1阻断的临床结果的整合分子和临床模型

2019-12-02606
OAAI